Canada markets closed
  • S&P/TSX

    20,659.99
    -489.01 (-2.31%)
     
  • S&P 500

    4,567.00
    -88.27 (-1.90%)
     
  • DOW

    34,483.72
    -652.22 (-1.86%)
     
  • CAD/USD

    0.7827
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    66.92
    +0.74 (+1.12%)
     
  • BTC-CAD

    72,657.21
    -1,449.32 (-1.96%)
     
  • CMC Crypto 200

    1,456.40
    +13.62 (+0.94%)
     
  • GOLD FUTURES

    1,774.20
    -2.30 (-0.13%)
     
  • RUSSELL 2000

    2,198.91
    -43.07 (-1.92%)
     
  • 10-Yr Bond

    1.4430
    -0.0870 (-5.69%)
     
  • NASDAQ futures

    16,220.75
    +70.25 (+0.43%)
     
  • VOLATILITY

    27.19
    +4.23 (+18.42%)
     
  • FTSE

    7,059.45
    -50.50 (-0.71%)
     
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     
  • CAD/EUR

    0.6905
    -0.0040 (-0.58%)
     

Bluechiip Limited (BCT.AX) Quarterly Activities Report

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Bluechiip Limited
Bluechiip Limited

Bluechiip Limited (BCT.AX) Quarterly Activities Report

Melbourne, Australia, Oct 28, 2021 - (ABN Newswire) - Bluechiip Limited (ASX:BCT) (HAM:1BL), a developer and leader in wireless tracking solutions for the healthcare and life science, security, defence and manufacturing industries, is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 30 September 2021.

ACTIVITIES REPORT FOR THE QUARTER ENDED 30 SEPTEMBER 2021

Corporate and Business updates for the Quarter

- Signed a two-year Licence and Development Agreement with California based FUJIFILM Irvine Scientific, Inc.;

- Successful progress towards global release of Bluechiip's direct to market portfolio of products for the Biobanking market including a range of Bluechiip Enabled and Bluechiip-branded range of cryogenic consumables;

- Received formal CE Marking (CE IVD) registration for Bluechiip Enabled cryovials providing Bluechiip direct access to the European Union market;

- Initial purchase orders received from local and overseas customers for Bluechiip's new range of consumables, readers and software. including delivery and installation in October 2021;

- Optimisation stage of the chip commercial production well in progress; and

- Closing cash and cash equivalents of $4.89m as at 30 September 2021, with no borrowings.

To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/3G600HZH


About Bluechiip Limited:


Bluechiip Limited (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Contact:

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au

Source:
Bluechiip Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting